Evidence map›Paper›PMID 41484308›Full record

ArticleScientific reports2026

A causal deep learning approach to identifying metabolic signatures of cognitive and functional decline in alzheimer's disease.

B Priyadarshini, John Sahaya Rani Alex

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

B PriyadarshiniSchool of Electronics Engineering, Vellore Institute of Technology, Chennai, India.
John Sahaya Rani AlexSchool of Electronics Engineering, Vellore Institute of Technology, Chennai, India. jsranialex@vit.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cognitive and functional decline in Alzheimer's disease (AD) arises from disruptions in specific brain networks. Identifying the most affected regions is essential for understanding disease progression and developing targeted interventions. Fluorodeoxyglucose positron emission tomography (FDG-PET) offers a sensitive method for detecting early metabolic dysfunction, often before structural changes become apparent. We examined regional brain glucose metabolism in relation to cognitive performance and functional independence across cognitively normal individuals, those with mild cognitive impairment (MCI), and AD patients. Cognitive function was measured using the Mini-Mental State Examination (MMSE), and daily functioning was assessed via the Functional Activities Questionnaire (FAQ). Imaging and clinical data were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Structural causal modeling was used to identify brain regions with a strong causal influence on MMSE and FAQ scores. These causally validated regions were then used as input to the proposed FDG-PET-based Cognition Prediction Network (FDG CogNet), a deep learning model, which includes a feature-wise attention mechanism to dynamically weight each region's contribution to prediction. Temporal, parietal, and hippocampal regions were most influential for cognitive performance, particularly in early stages of disease. Functional abilities were more strongly associated with executive and integrative regions, including the angular gyrus, temporal poles, posterior cingulate, and frontal cortices. Cerebellar regions showed compensatory activity in MCI but diminished in AD, suggesting reduced neural resilience. FDG CogNet achieved high predictive accuracy, with R² = 0.90 for MMSE and R² = 0.94 for FAQ, demonstrating that limiting inputs to causally relevant regions improved both performance and interpretability. These findings clarify stage-specific neural mechanisms in AD and show that combining causal inference with an attention-based deep learning model provides a powerful framework for accurate and interpretable prediction. This approach highlights the clinical utility of FDG PET for early diagnosis and suggests that timely, region-specific interventions offer the best opportunity to preserve cognitive and functional abilities in AD.

Indexed as

Alzheimer DiseaseCognitionCognitive DysfunctionDeep LearningAgedAged, 80 and overBrainFemaleFluorodeoxyglucose F18HumansMalePositron-Emission TomographyFluorodeoxyglucose F18Alzheimer’s diseaseBrain glucose metabolismCausal inferenceCognitive declineFAQFDG-PETFeature-wise attention mechanism.Functional impairmentMMSE

Identifiers

PMID41484308
PMCPMC12827273

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.